English
简体中文
Total: £ 56.28
Published Date: 2026-01-20 | Pages: 110 | Tables: 115 | Pharma & Healthcare
The global Hyperuricemia Micromolecular Drugs market was valued at US$ 3164 million in 2025 and is anticipated to reach US$ 5628 million by 2032, at a CAGR of 8.7% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Hyperuricemia Micromolecular Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Hyperuricemia micromolecular drugs refer to a class of chemical drugs with small molecular weight, which can enter the body through oral administration and specifically act on enzymes or receptors in the uric acid metabolism pathway, thereby reducing the level of uric acid in blood. They are mainly used for the treatment and prevention of hyperuricemia and its related diseases such as gout.
The North American market for Hyperuricemia Micromolecular Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Hyperuricemia Micromolecular Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Hyperuricemia Micromolecular Drugs include Casper Pharma LLC, GSK PLC, ASKA Pharmaceutical Holdings Co., Ltd, Pfizer Inc., Takeda Pharmaceutical Co., Ltd, Viatris, Inc., Menarini International Operations, Suzuken Co., Ltd., Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd., Eisai Co., Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Hyperuricemia Micromolecular Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hyperuricemia Micromolecular Drugs. The Hyperuricemia Micromolecular Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Hyperuricemia Micromolecular Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Hyperuricemia Micromolecular Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Casper Pharma LLC
GSK PLC
ASKA Pharmaceutical Holdings Co., Ltd
Pfizer Inc.
Takeda Pharmaceutical Co., Ltd
Viatris, Inc.
Menarini International Operations
Suzuken Co., Ltd.
Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Segment by Type
25-100 mg
100-300 mg
by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Hyperuricemia Micromolecular Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Hyperuricemia Micromolecular Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Hyperuricemia Micromolecular Drugs Market Overview
1.1 Product Definition
1.2 Hyperuricemia Micromolecular Drugs by Type
1.2.1 Global Hyperuricemia Micromolecular Drugs Market Value by Type: 2025 vs 2032
1.2.2 25-100 mg
1.2.3 100-300 mg
1.3 Hyperuricemia Micromolecular Drugs by Application
1.3.1 Global Hyperuricemia Micromolecular Drugs Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Hyperuricemia Micromolecular Drugs Market Size Estimates and Forecasts
1.4.1 Global Hyperuricemia Micromolecular Drugs Revenue 2021–2032
1.4.2 Global Hyperuricemia Micromolecular Drugs Sales 2021–2032
1.4.3 Global Hyperuricemia Micromolecular Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Hyperuricemia Micromolecular Drugs Market Competition by Manufacturers
2.1 Global Hyperuricemia Micromolecular Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Hyperuricemia Micromolecular Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Hyperuricemia Micromolecular Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Date of Entry into the Industry
2.8 Global Hyperuricemia Micromolecular Drugs Market Competitive Situation and Trends
2.8.1 Global Hyperuricemia Micromolecular Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Hyperuricemia Micromolecular Drugs Players Market Share by Revenue
2.8.3 Global Hyperuricemia Micromolecular Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hyperuricemia Micromolecular Drugs Market Scenario by Region
3.1 Global Hyperuricemia Micromolecular Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Hyperuricemia Micromolecular Drugs Sales by Region: 2021–2032
3.2.1 Global Hyperuricemia Micromolecular Drugs Sales by Region: 2021–2026
3.2.2 Global Hyperuricemia Micromolecular Drugs Sales by Region: 2027–2032
3.3 Global Hyperuricemia Micromolecular Drugs Revenue by Region: 2021–2032
3.3.1 Global Hyperuricemia Micromolecular Drugs Revenue by Region: 2021–2026
3.3.2 Global Hyperuricemia Micromolecular Drugs Revenue by Region: 2027–2032
3.4 North America Hyperuricemia Micromolecular Drugs Market Facts & Figures by Country
3.4.1 North America Hyperuricemia Micromolecular Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Hyperuricemia Micromolecular Drugs Sales by Country (2021–2032)
3.4.3 North America Hyperuricemia Micromolecular Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hyperuricemia Micromolecular Drugs Market Facts & Figures by Country
3.5.1 Europe Hyperuricemia Micromolecular Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Hyperuricemia Micromolecular Drugs Sales by Country (2021–2032)
3.5.3 Europe Hyperuricemia Micromolecular Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hyperuricemia Micromolecular Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Hyperuricemia Micromolecular Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Hyperuricemia Micromolecular Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Hyperuricemia Micromolecular Drugs Market Facts & Figures by Country
3.7.1 Latin America Hyperuricemia Micromolecular Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Hyperuricemia Micromolecular Drugs Sales by Country (2021–2032)
3.7.3 Latin America Hyperuricemia Micromolecular Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Hyperuricemia Micromolecular Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hyperuricemia Micromolecular Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Hyperuricemia Micromolecular Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hyperuricemia Micromolecular Drugs Sales by Type (2021–2032)
4.1.1 Global Hyperuricemia Micromolecular Drugs Sales by Type (2021–2026)
4.1.2 Global Hyperuricemia Micromolecular Drugs Sales by Type (2027–2032)
4.1.3 Global Hyperuricemia Micromolecular Drugs Sales Market Share by Type (2021–2032)
4.2 Global Hyperuricemia Micromolecular Drugs Revenue by Type (2021–2032)
4.2.1 Global Hyperuricemia Micromolecular Drugs Revenue by Type (2021–2026)
4.2.2 Global Hyperuricemia Micromolecular Drugs Revenue by Type (2027–2032)
4.2.3 Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Hyperuricemia Micromolecular Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Hyperuricemia Micromolecular Drugs Sales by Application (2021–2032)
5.1.1 Global Hyperuricemia Micromolecular Drugs Sales by Application (2021–2026)
5.1.2 Global Hyperuricemia Micromolecular Drugs Sales by Application (2027–2032)
5.1.3 Global Hyperuricemia Micromolecular Drugs Sales Market Share by Application (2021–2032)
5.2 Global Hyperuricemia Micromolecular Drugs Revenue by Application (2021–2032)
5.2.1 Global Hyperuricemia Micromolecular Drugs Revenue by Application (2021–2026)
5.2.2 Global Hyperuricemia Micromolecular Drugs Revenue by Application (2027–2032)
5.2.3 Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Hyperuricemia Micromolecular Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Casper Pharma LLC
6.1.1 Casper Pharma LLC Company Information
6.1.2 Casper Pharma LLC Description and Business Overview
6.1.3 Casper Pharma LLC Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Casper Pharma LLC Hyperuricemia Micromolecular Drugs Product Portfolio
6.1.5 Casper Pharma LLC Recent Developments/Updates
6.2 GSK PLC
6.2.1 GSK PLC Company Information
6.2.2 GSK PLC Description and Business Overview
6.2.3 GSK PLC Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GSK PLC Hyperuricemia Micromolecular Drugs Product Portfolio
6.2.5 GSK PLC Recent Developments/Updates
6.3 ASKA Pharmaceutical Holdings Co., Ltd
6.3.1 ASKA Pharmaceutical Holdings Co., Ltd Company Information
6.3.2 ASKA Pharmaceutical Holdings Co., Ltd Description and Business Overview
6.3.3 ASKA Pharmaceutical Holdings Co., Ltd Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 ASKA Pharmaceutical Holdings Co., Ltd Hyperuricemia Micromolecular Drugs Product Portfolio
6.3.5 ASKA Pharmaceutical Holdings Co., Ltd Recent Developments/Updates
6.4 Pfizer Inc.
6.4.1 Pfizer Inc. Company Information
6.4.2 Pfizer Inc. Description and Business Overview
6.4.3 Pfizer Inc. Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Inc. Hyperuricemia Micromolecular Drugs Product Portfolio
6.4.5 Pfizer Inc. Recent Developments/Updates
6.5 Takeda Pharmaceutical Co., Ltd
6.5.1 Takeda Pharmaceutical Co., Ltd Company Information
6.5.2 Takeda Pharmaceutical Co., Ltd Description and Business Overview
6.5.3 Takeda Pharmaceutical Co., Ltd Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Takeda Pharmaceutical Co., Ltd Hyperuricemia Micromolecular Drugs Product Portfolio
6.5.5 Takeda Pharmaceutical Co., Ltd Recent Developments/Updates
6.6 Viatris, Inc.
6.6.1 Viatris, Inc. Company Information
6.6.2 Viatris, Inc. Description and Business Overview
6.6.3 Viatris, Inc. Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Viatris, Inc. Hyperuricemia Micromolecular Drugs Product Portfolio
6.6.5 Viatris, Inc. Recent Developments/Updates
6.7 Menarini International Operations
6.7.1 Menarini International Operations Company Information
6.7.2 Menarini International Operations Description and Business Overview
6.7.3 Menarini International Operations Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Menarini International Operations Hyperuricemia Micromolecular Drugs Product Portfolio
6.7.5 Menarini International Operations Recent Developments/Updates
6.8 Suzuken Co., Ltd.
6.8.1 Suzuken Co., Ltd. Company Information
6.8.2 Suzuken Co., Ltd. Description and Business Overview
6.8.3 Suzuken Co., Ltd. Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Suzuken Co., Ltd. Hyperuricemia Micromolecular Drugs Product Portfolio
6.8.5 Suzuken Co., Ltd. Recent Developments/Updates
6.9 Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd.
6.9.1 Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Company Information
6.9.2 Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Description and Business Overview
6.9.3 Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Hyperuricemia Micromolecular Drugs Product Portfolio
6.9.5 Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Recent Developments/Updates
6.10 Eisai Co., Ltd.
6.10.1 Eisai Co., Ltd. Company Information
6.10.2 Eisai Co., Ltd. Description and Business Overview
6.10.3 Eisai Co., Ltd. Hyperuricemia Micromolecular Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eisai Co., Ltd. Hyperuricemia Micromolecular Drugs Product Portfolio
6.10.5 Eisai Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hyperuricemia Micromolecular Drugs Industry Chain Analysis
7.2 Hyperuricemia Micromolecular Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hyperuricemia Micromolecular Drugs Production Mode & Process Analysis
7.4 Hyperuricemia Micromolecular Drugs Sales and Marketing
7.4.1 Hyperuricemia Micromolecular Drugs Sales Channels
7.4.2 Hyperuricemia Micromolecular Drugs Distributors
7.5 Hyperuricemia Micromolecular Drugs Customer Analysis
8 Hyperuricemia Micromolecular Drugs Market Dynamics
8.1 Hyperuricemia Micromolecular Drugs Industry Trends
8.2 Hyperuricemia Micromolecular Drugs Market Drivers
8.3 Hyperuricemia Micromolecular Drugs Market Challenges
8.4 Hyperuricemia Micromolecular Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Hyperuricemia Micromolecular Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Hyperuricemia Micromolecular Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Hyperuricemia Micromolecular Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Hyperuricemia Micromolecular Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Hyperuricemia Micromolecular Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Hyperuricemia Micromolecular Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Hyperuricemia Micromolecular Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hyperuricemia Micromolecular Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Hyperuricemia Micromolecular Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hyperuricemia Micromolecular Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Casper Pharma LLC Company Information
Table 71. Casper Pharma LLC Description and Business Overview
Table 72. Casper Pharma LLC Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Casper Pharma LLC Hyperuricemia Micromolecular Drugs Product
Table 74. Casper Pharma LLC Recent Developments/Updates
Table 75. GSK PLC Company Information
Table 76. GSK PLC Description and Business Overview
Table 77. GSK PLC Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. GSK PLC Hyperuricemia Micromolecular Drugs Product
Table 79. GSK PLC Recent Developments/Updates
Table 80. ASKA Pharmaceutical Holdings Co., Ltd Company Information
Table 81. ASKA Pharmaceutical Holdings Co., Ltd Description and Business Overview
Table 82. ASKA Pharmaceutical Holdings Co., Ltd Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. ASKA Pharmaceutical Holdings Co., Ltd Hyperuricemia Micromolecular Drugs Product
Table 84. ASKA Pharmaceutical Holdings Co., Ltd Recent Developments/Updates
Table 85. Pfizer Inc. Company Information
Table 86. Pfizer Inc. Description and Business Overview
Table 87. Pfizer Inc. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Inc. Hyperuricemia Micromolecular Drugs Product
Table 89. Pfizer Inc. Recent Developments/Updates
Table 90. Takeda Pharmaceutical Co., Ltd Company Information
Table 91. Takeda Pharmaceutical Co., Ltd Description and Business Overview
Table 92. Takeda Pharmaceutical Co., Ltd Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Takeda Pharmaceutical Co., Ltd Hyperuricemia Micromolecular Drugs Product
Table 94. Takeda Pharmaceutical Co., Ltd Recent Developments/Updates
Table 95. Viatris, Inc. Company Information
Table 96. Viatris, Inc. Description and Business Overview
Table 97. Viatris, Inc. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Viatris, Inc. Hyperuricemia Micromolecular Drugs Product
Table 99. Viatris, Inc. Recent Developments/Updates
Table 100. Menarini International Operations Company Information
Table 101. Menarini International Operations Description and Business Overview
Table 102. Menarini International Operations Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Menarini International Operations Hyperuricemia Micromolecular Drugs Product
Table 104. Menarini International Operations Recent Developments/Updates
Table 105. Suzuken Co., Ltd. Company Information
Table 106. Suzuken Co., Ltd. Description and Business Overview
Table 107. Suzuken Co., Ltd. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Suzuken Co., Ltd. Hyperuricemia Micromolecular Drugs Product
Table 109. Suzuken Co., Ltd. Recent Developments/Updates
Table 110. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Company Information
Table 111. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Description and Business Overview
Table 112. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Hyperuricemia Micromolecular Drugs Product
Table 114. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 115. Eisai Co., Ltd. Company Information
Table 116. Eisai Co., Ltd. Description and Business Overview
Table 117. Eisai Co., Ltd. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eisai Co., Ltd. Hyperuricemia Micromolecular Drugs Product
Table 119. Eisai Co., Ltd. Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Hyperuricemia Micromolecular Drugs Distributors List
Table 123. Hyperuricemia Micromolecular Drugs Customers List
Table 124. Hyperuricemia Micromolecular Drugs Market Trends
Table 125. Hyperuricemia Micromolecular Drugs Market Drivers
Table 126. Hyperuricemia Micromolecular Drugs Market Challenges
Table 127. Hyperuricemia Micromolecular Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Hyperuricemia Micromolecular Drugs
Figure 2. Global Hyperuricemia Micromolecular Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Hyperuricemia Micromolecular Drugs Market Share by Type: 2025 & 2032
Figure 4. 25-100 mg Product Picture
Figure 5. 100-300 mg Product Picture
Figure 6. Global Hyperuricemia Micromolecular Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Hyperuricemia Micromolecular Drugs Market Share by Application: 2025 & 2032
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global Hyperuricemia Micromolecular Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Hyperuricemia Micromolecular Drugs Market Size (US$ Million), 2021–2032
Figure 13. Global Hyperuricemia Micromolecular Drugs Sales (K Units), 2021–2032
Figure 14. Global Hyperuricemia Micromolecular Drugs Average Price (US$/Unit), 2021–2032
Figure 15. Hyperuricemia Micromolecular Drugs Report Years Considered
Figure 16. Hyperuricemia Micromolecular Drugs Sales Share by Manufacturers in 2025
Figure 17. Global Hyperuricemia Micromolecular Drugs Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Hyperuricemia Micromolecular Drugs Players: Market Share by Revenue in Hyperuricemia Micromolecular Drugs in 2025
Figure 19. Hyperuricemia Micromolecular Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Hyperuricemia Micromolecular Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 22. North America Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 23. United States Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 26. Europe Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 27. Germany Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Hyperuricemia Micromolecular Drugs Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue Market Share by Region (2021–2032)
Figure 34. China Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 42. Latin America Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Hyperuricemia Micromolecular Drugs by Type (2021–2032)
Figure 53. Global Revenue Market Share of Hyperuricemia Micromolecular Drugs by Type (2021–2032)
Figure 54. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Hyperuricemia Micromolecular Drugs by Application (2021–2032)
Figure 56. Global Revenue Market Share of Hyperuricemia Micromolecular Drugs by Application (2021–2032)
Figure 57. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Application (2021–2032)
Figure 58. Hyperuricemia Micromolecular Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
